Zaggle buys two companies in a single day, pumps Rs. 150 crore
The company is set to acquire a 100% stake in Dice and GreenEdge
The company has made four acquisitions in the last four months, infusing about Rs. 215 crore
MUMBAI, India , June 9, 2025 /PRNewswire/ — Zaggle Prepaid Ocean Services Limited, India's leading spend management company, is set to acquire a 100% stake in Dice and GreenEdge Enterprises for ₹150 crore. These consecutive acquisitions will enhance Zaggle's presence in the Indian market, significantly broaden its portfolio of advanced spend management solutions and further strengthen its offerings in the loyalty, rewards and travel segments.
With this acquisition, Zaggle has completed four strategic takeovers in the past four months, totalling nearly ₹215 crore. These moves align with the company's ambition to become a $1 billion revenue enterprise within the next five to seven years. Zaggle is strategically deploying the ₹595 crore raised through its Qualified Institutional Placement (QIP) to acquire companies that are product-accretive, geography-accretive, or EBITDA-accretive, while ensuring sustained positive returns on equity and investments.
Incorporated in 2018, Dice is a Pune -based AI-driven enterprise spend management platform, specializing in Spending as a Service. Its suite of solutions encompasses travel and expense management, accounts payable management and procurement management solutions. Its unified platform offers seamless self-booking, approvals and reconciliations with built-in policy controls, streamlining the entire spend cycle for businesses. The company has demonstrated consistent growth over the last two years, clocking a turnover of over Rs. 6 crores in FY24.
The acquisition of Dice will significantly enhance Zaggle's existing product portfolio, transforming it into a more comprehensive and integrated suite of spend management solutions. Through this acquisition, Zaggle will gain access to Dice's established customer base, which includes prominent enterprises such as Tata AIA, Bajaj Electricals and DTDC, further reinforcing its market presence. The combined capabilities will not only deepen Zaggle's reach within the Indian market but also create new opportunities to deliver its advanced solutions on a global scale.
GreenEdge Enterprises, on the other hand, is a specialized solution provider for golf travel, unique experiences and access-based rewards. With its stronghold in India , the company achieved a turnover of Rs. 19.82 c rores in FY24. This acquisition will enhance Zaggle's product offerings in the loyalty and rewards and travel segment, providing a substantial boost to its Propel offering.
Zaggle had recently announced the acquisition of a 51% Controlling Stake in EffiaSoft and a 38.34% stake in Mobileware Technologies. The company had recently reported a consolidated profit after tax (PAT) of Rs. 87.4 crore for FY25, up from Rs. 44 crore in FY24.
About Zaggle
Founded in 2011, Zaggle (BSE: 543985) (NSE: ZAGGLE) is a leading player in spend management, offering a differentiated value proposition with a diversified user base. Operating within the business-to-business-to-customer (B2B2C) segment, Zaggle stands out as one of the few companies with a comprehensive range of financial technology products and services. Zaggle is one of India's top issuers of prepaid cards, collaborating with banking partners to drive its card offerings. The company also boasts a diverse portfolio of SaaS products and an extensive network of touchpoints. As of March 31, 2025 , Zaggle has issued over 50 million prepaid cards, serves more than 3,400 corporate enterprise clients and supports a user base exceeding 3.2 million. With a robust corporate client base spanning various industries, including banking and finance, technology, healthcare, manufacturing, FMCG, infrastructure and automobiles, Zaggle is well-positioned as a leading player in the spend management sector.
For more information, please visit the company website www.zaggle.in or follow us on LinkedIn www.linkedin.com/company/zaggleapp/
View original content:https://www.prnewswire.com/in/news-releases/zaggle-buys-two-companies-in-a-single-day-pumps-rs-150-crore-302476260.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
38 minutes ago
- Business Upturn
Texmaco Rail & Engineering bags Rs 44 crore order from MRVC for traction-transformer works
By Aditya Bhagchandani Published on June 10, 2025, 17:34 IST Texmaco Rail & Engineering has informed the exchanges that it has won a contract worth Rs 44.04 crore from Mumbai Railway Vikas Corporation (MRVC) to supply, construct, install, test and commission traction transformers, sectioning posts (SPs) and related works for the third and fourth lines of Central Railway. In its disclosure, the company said the project involves setting up a 1×25 kV, 110/25 kV traction sub-station with 40/56 MVA AC traction transformers and two sectioning posts, together with all associated civil and electrical works. The work is entirely domestic, carries no related-party element, and must be completed within 18 months. Texmaco Rail & Engineering added that neither its promoter group nor any of its group companies holds an interest in MRVC. The order, awarded via a letter dated 9 June 2025, will be executed under the terms laid out in SEBI's November 2024 disclosure framework. This contract further strengthens the company's railway-electrification portfolio at a time when Indian Railways continues to expand high-capacity suburban corridors. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock-market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Entrepreneur
an hour ago
- Entrepreneur
Crafting Men's Confidence
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. What began as an ambition to offer Indian customers the same high-quality fashion that was being manufactured for global giants like Zara, Mango, and Marks & Spencer has today evolved into a profitable, Shark Tank-backed D2C menswear brand. The Bear House, co-founded by Harsh Somaiya, was born out of a belief that Indian consumers deserved better design, fit, and fabric—online. "We thought if an Indian factory can design and manufacture for global brands, why shouldn't Indian customers experience the same premium products and quality? At that time, there was a common perception that good quality products weren't available online. So we decided to change that narrative," said Somaiya. Built on the pillars of great design, fit, and affordability, The Bear House chose a D2C-first approach to maintain control over the entire customer experience. "That means no middlemen, no dilution of brand story," Somaiya explained. "This helped us build loyalty and get instant feedback, which shaped everything from fabric choices to fits." The brand's breakout success was its innovative take on flannel shirts—traditionally warm and heavy—which they re-engineered using lightweight 100% cotton to suit India's climate. "Our flannels have been a bestseller since day one and still contribute to 40% of our shirts revenue," shared Somaiya. With 85% of its sales coming from marketplaces like Myntra, Amazon, and Flipkart, the brand has built a strong digital footprint across over 20,000 pincodes and has a loyal customer base of 20 lakh. It has also stepped into offline retail with stores in Bengaluru and Hyderabad, and is eyeing 10–15 more stores by FY 2025–26. Quick commerce, though a non-traditional fit for fashion, is another frontier the brand is testing. "We've made select collections available on Zepto as a strategic experiment and are noticing good results," said Somaiya. "We're confident that quick commerce fashion will be essential going forward." Internationally, The Bear House has begun its foray into the Middle East and is exploring further global expansion. Closer home, tech-enabled personalisation and new lifestyle categories are on the roadmap. "From bootstrapping to now building a brand with depth, it's been incredibly fulfilling," reflected Somaiya. "At the heart of it, we believe today's men don't just want clothes—they want brands with soul." Facts:
Yahoo
2 hours ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
